RxDoctor Payments Data

Lori Gregory

Family · Oakland, MDNPI 1275086274

Payments from drug & device makers

$255in general payments, 2019–2025

Across 16 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$44
  • Pfizer$42
  • Novo Nordisk$37
  • Indivior Inc.$25
  • Abbott$18
  • Insulet Corporation$16
  • plus $72 from 5 others

What the payments were for

  • Food & beverage$255100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$255 in reported general payments places this provider in the 45th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$3,265
Medicare patients
112
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$95,538
EliquisApixaban49$49,778
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$28,249
JardianceEmpagliflozin11$18,581
Tresiba Flextouch U-200Insulin Degludec26$18,507
XareltoRivaroxaban11$13,569
Tresiba Flextouch U-100Insulin Degludec13$12,119
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,216
Fentanyl23$4,769
ShingrixVaricella-Zoster Ge/As01b/Pf23$4,390
Atorvastatin Calcium341$3,724
Levemir FlexpenInsulin Detemir12$3,639
Gabapentin193$3,279
Albuterol Sulfate HfaAlbuterol Sulfate84$2,892
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen111$2,868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$37$95,53882 claims
PfizerEliquis$42$49,77849 claims
Boehringer IngelheimJardiance$15$18,58111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,843 family providers in Maryland.

Other family in Oakland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →